• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination of Immunotherapy and Radiotherapy-The Next Magic Step in the Management of Lung Cancer?

作者信息

Hendriks Lizza E L, Menis Jessica, De Ruysscher Dirk K M, Reck Martin

机构信息

Department of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands.

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy.

出版信息

J Thorac Oncol. 2020 Feb;15(2):166-169. doi: 10.1016/j.jtho.2019.12.106.

DOI:10.1016/j.jtho.2019.12.106
PMID:32127183
Abstract
摘要

相似文献

1
Combination of Immunotherapy and Radiotherapy-The Next Magic Step in the Management of Lung Cancer?免疫疗法与放射疗法的联合——肺癌治疗的下一个神奇步骤？
J Thorac Oncol. 2020 Feb;15(2):166-169. doi: 10.1016/j.jtho.2019.12.106.
2
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?单独使用PD-1检查点阻断疗法或联合使用PD-1和CTLA-4阻断疗法作为肺癌的免疫疗法？
Expert Opin Biol Ther. 2017 Mar;17(3):305-312. doi: 10.1080/14712598.2017.1280454. Epub 2017 Jan 18.
3
Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.小细胞肺癌化疗、免疫治疗和检查点阻断的理由：超越传统治疗方法。
J Thorac Oncol. 2013 May;8(5):587-98. doi: 10.1097/JTO.0b013e318286cf88.
4
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
5
Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential.免疫检查点抑制剂在小细胞肺癌中的应用：部分实现的潜力。
Adv Ther. 2019 Aug;36(8):1826-1832. doi: 10.1007/s12325-019-01008-2. Epub 2019 Jun 17.
6
Immune checkpoint inhibitors in lung cancer: current status and future directions.肺癌中的免疫检查点抑制剂：现状与未来方向。
Chin Clin Oncol. 2017 Apr;6(2):17. doi: 10.21037/cco.2017.02.05.
7
Immunotherapy for small cell lung cancer: mechanisms of resistance.小细胞肺癌的免疫治疗：耐药机制。
Expert Opin Biol Ther. 2019 May;19(5):423-432. doi: 10.1080/14712598.2019.1592155. Epub 2019 Mar 18.
8
[Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].[非小细胞肺癌——从免疫生物学到免疫治疗]
Klin Onkol. 2016 Fall;29 Suppl 4(Suppl 4):78-87.
9
Expanding the Role of Immunotherapy to Limited-Stage SCLC.扩大免疫疗法在局限期小细胞肺癌中的作用。
J Thorac Oncol. 2020 Dec;15(12):1806-1808. doi: 10.1016/j.jtho.2020.09.021.
10
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.明智选择非小细胞肺癌（NSCLC）一线免疫治疗：该加什么，该弃什么。
Cancer Treat Rev. 2019 May;75:39-51. doi: 10.1016/j.ctrv.2019.03.004. Epub 2019 Mar 28.

引用本文的文献

1
Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.代谢和营养紊乱对非小细胞肺癌放疗与免疫治疗协同作用的影响。
BMC Cancer. 2025 May 27;25(1):948. doi: 10.1186/s12885-025-14278-7.
2
Atypical Response in Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Radiographic Patterns and Clinical Value of Local Therapy.PD-1/PD-L1抑制剂治疗转移性非小细胞肺癌的非典型反应：影像学表现及局部治疗的临床价值
Cancers (Basel). 2022 Dec 28;15(1):180. doi: 10.3390/cancers15010180.
3
Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review.
早期非小细胞肺癌与晚期非小细胞肺癌免疫治疗疗效比较：系统评价。
BMC Med. 2022 Nov 7;20(1):426. doi: 10.1186/s12916-022-02580-1.
4
Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.接受PD-1/PD-L1抑制剂治疗的晚期非小细胞肺癌患者基于性别的临床结局——一项回顾性双中心队列研究
Cancers (Basel). 2021 Dec 24;14(1):93. doi: 10.3390/cancers14010093.
5
Tumour burden and efficacy of immune-checkpoint inhibitors.肿瘤负担与免疫检查点抑制剂的疗效。
Nat Rev Clin Oncol. 2022 Feb;19(2):75-90. doi: 10.1038/s41571-021-00564-3. Epub 2021 Oct 12.
6
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.免疫治疗时代可切除的Ⅲ-N2期非小细胞肺癌（NSCLC）的管理
Cancers (Basel). 2021 Sep 26;13(19):4811. doi: 10.3390/cancers13194811.
7
How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.如何在寡转移非小细胞肺癌试验中优化免疫治疗的纳入：一项叙述性综述
Transl Lung Cancer Res. 2021 Jul;10(7):3486-3502. doi: 10.21037/tlcr-20-1065.
8
Targeted Liquid Biopsy Using Irradiation to Facilitate the Release of Cell-Free DNA from a Spatially Aimed Tumor Tissue.靶向液体活检利用辐照促进空间靶向肿瘤组织中游离 DNA 的释放。
Cancer Res Treat. 2022 Jan;54(1):40-53. doi: 10.4143/crt.2021.151. Epub 2021 May 25.
9
Progress in immunotherapy for small cell lung cancer.小细胞肺癌免疫治疗的进展
World J Clin Oncol. 2020 Jun 24;11(6):370-377. doi: 10.5306/wjco.v11.i6.370.